Navigation Links
Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
Date:4/17/2008

-----------------------

Transfusion Therapies (2)

United States $31 $43 (28%) (28%)

International 13 45 (71%) (73%)

Total $44 $88 (50%) (51%)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Baxter International Inc.

United States $1,179 $1,139 4% 4%

International 1,698 1,536 11% 1%

Total $2,877 $2,675 8% 2%

-------------------------------------------------------------------------

(1) Prior year BioScience sales data has been reclassified as described in

Note 2.

(2) The Transfusion Therapies (TT) business was sold on February 28, 2007.

The results of operations of the TT business were previously reported

in the BioScience business. The TT totals above include sales of TT

products through the date of divestiture, as well as revenues

associated with manufacturing, distribution and other services

provided by the company to the buyer of the TT business

post-divestiture.

BAXTER INTERNATIONAL INC.

Key Product Line Sales

Periods Ending March 31, 2008 and 2007

(unaudited)

($ in millions)

--------------------------------------------------------------------------

%Growth %Growth

@ @

Q1 Q1 Actual Constant


'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
2. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
3. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
4. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
5. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
6. Baxter Kidney Patient Education Program Celebrates Tenth Anniversary
7. Baxter Receives 510(k) Clearance From FDA For V-Link With VitalShield, New Antimicrobial Intravascular Technology
8. Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit
9. Baxter International Fourth Quarter 2007 Financial Results Conference Call
10. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
11. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Repligen Corporation (Nasdaq: RGEN ) ... in research funding to support the ongoing development ... Muscular Dystrophy Association (MDA). This grant will ... and GMP manufacture of a drug candidate for ... not only provides important funding for Repligen,s research ...
(Date:12/15/2009)... Atomic Force Microscopy (AFM) have been developed and are opening ... liquid/air interface. The NeedleProbes’ cylindrical geometry enables researchers to ... viscosity - all in a single force distance curve. ... ... New, constant diameter NeedleProbes are enabling unique measurements ...
(Date:12/15/2009)... LONDON, Dec. 15 Thomson ... Pharma ® has become the first drug pipeline ... and outcome information. This highly anticipated new content ... this month. ,, Thomson Pharma ... from registries, publications, press releases, conferences, and other ...
(Date:12/14/2009)... Fla., Dec. 14 Dyadic International, Inc. ... has extended its collaboration with The Scripps Research ... Scripps to re-annotate the genome of Dyadic,s patented ... is a continuation of the successful relationship between ... when Dyadic engaged Scripps to annotate the C1 ...
Breaking Biology Technology:Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 2Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program 3New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 2New Constant Diameter NeedleProbes™ with Unique Ability to Measure Liquid Surface Properties by AFM 3Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5
... Calif., Dec. 3 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ... host a conference call with simultaneous webcast,on Sunday, December 7, ... Phase 2 clinical trial of R788, an oral Syk kinase ... Conference Call and Webcast Information , ...
... , QUEBEC CITY, Dec. 3 ... ; TSX: AEZ), a global biopharmaceutical company focused on ... the transaction under the previously announced purchase and sale ... to AEterna Zentaris, rights to royalties on future sales ...
... for OGX-011 in combination with docetaxel and prednisone and ... for docetaxel and prednisone alone., Achievement of ... all ... WA and VANCOUVER, Dec. 3 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ...
Other Biology Technology:Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4
(Date:12/15/2009)... Economics, environmental impacts, social dynamics, and production ... overall success of an agroecosystem. Positive or negative, ... individuals and social groups to continuously adapt farming ... , Experiential learning theory suggests that knowledge is ... Such lessons are especially valuable for environmental and ...
(Date:12/15/2009)... team of Spanish and American researchers found the fossil remains ... Now they have published, for the first time, the results ... death of the young cetacean, possibly a baleen whale from ... of the partial fossil remains of a whale from the ... sedimentary formation, but it is the first time that the ...
(Date:12/15/2009)... 15 The PTR Group, a leading real-time ... it has agreed to sponsor three high school teams ... Competition ( http://usfirst.org ). ,, The PTR ... in three different states. The teams from Atholton ... and James Madison HS in Vienna, VA all have ...
Breaking Biology News(10 mins):Experiential learning teaches change and adaptation 2Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2
... resulting from purifying drinking water with chlorine boost the ... by the results of a major new study. If ... likely are modest, it concludes. , The national study, ... scientists, contrasts with earlier, less detailed work done in ...
... method for manipulating macromolecules has been developed by researchers ... uses double-stranded DNA to direct the behavior of other ... has been used as a static lattice to construct ... alone into such shapes, the researchers are using DNA ...
... of researchers at the Universitat Autònoma de Barcelona has ... have the same size and thickness as a fingernail ... to several minutes or a few hours, depending on ... different tasks, ranging from paternity tests and identifying people ...
Other Biology News:Major new UNC-based drinking water study suggests pregnancy fears may be overstated 2Major new UNC-based drinking water study suggests pregnancy fears may be overstated 3Health costs soar as 60 million Americans classed as obese 2New miniaturised chip dramatically reduces time taken for DNA analysis 2New miniaturised chip dramatically reduces time taken for DNA analysis 3
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, all ... Ontology classification, are arrayed in quadruplicate ... and a specific chip layout guarantee ...
...
... E.Coli glycerol stocks contained in standard 96-well ... clones with approximately 5,000 clones per plate. ... plate well, the corresponding subplate is screened ... the positive well(s). Cells from a positive ...
Biology Products: